Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study
Authors: Bukkems V, Necsoi C, Hidalgo Tenorio C, et al. PANNA Network
Published in: Clin infect Dis. 2020; 24;ciaa488.
Abstract This phase-IV study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 HIV-1-positive women. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir Ctrough was reduced by 77%, with 85% of pregnant women having a Ctrough below the EC90.